News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

Opinion|Videos|August 28, 2024

Early Diagnosis and Treatment for Central Precocious Puberty

Author(s)Karen O. Klein, MD, Jill Samis, MD , Aviva B. Sopher, MD, MS

The panel explores the impact of early versus delayed diagnosis and treatment initiation on long-term outcomes in Central Precocious Puberty patients.

Episodes in this series

3 KOLs are featured in this series.

EP. 1 Overview Of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 2 Diagnosis of Central Precocious Puberty and its Psychosocial Impact

3 KOLs are featured in this series.

EP. 3 Early Diagnosis and Treatment for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 4 Treatment Options for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 5 Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty

3 KOLs are featured in this series.

EP. 6 Individualized Management of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 7 Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions

3 KOLs are featured in this series.

EP. 8 Central Precocious Puberty in Male Patients

3 KOLs are featured in this series.

EP. 9 Recommendations and Outlook for Central Precocious Puberty

Video content above is prompted by the following:

How might an early CPP diagnosis and subsequent treatment initiation affect outcomes, compared to a later start?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Latest CME

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Jay B. Wish, MD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA updates Elevidys labeling with boxed warning and revised indication following reports of fatal liver injury

Tapinarof cream, 1% (VTAMA) shows early improvements in pediatric atopic dermatitis

Valeria Cohran, MD, highlights specialist-pediatrician collaboration when treating short bowel syndrome-associated intestinal failure

Valeria Cohran, MD, discusses teduglutide response in children with SBS-IF

Neurodevelopmental disorder risks not increased by prenatal acetaminophen use

© 2025 MJH Life Sciences^®

All rights reserved.